247 related articles for article (PubMed ID: 17178794)
21. Fighting tuberculosis by drugs targeting nonreplicating
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
[TBL] [Abstract][Full Text] [Related]
22. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
Malone RS; Fish DN; Spiegel DM; Childs JM; Peloquin CA
Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1580-4. PubMed ID: 10228130
[TBL] [Abstract][Full Text] [Related]
23. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Alvirez-Freites EJ; Carter JL; Cynamon MH
Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
[TBL] [Abstract][Full Text] [Related]
25. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
Nuermberger EL; Yoshimatsu T; Tyagi S; Williams K; Rosenthal I; O'Brien RJ; Vernon AA; Chaisson RE; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2004 Nov; 170(10):1131-4. PubMed ID: 15306535
[TBL] [Abstract][Full Text] [Related]
26. [R207910 (TMC207): a new antibiotic for the treatment of tuberculosis].
Lounis N; Guillemont J; Veziris N; Koul A; Jarlier V; Andries K
Med Mal Infect; 2010 Jul; 40(7):383-90. PubMed ID: 19954909
[TBL] [Abstract][Full Text] [Related]
27. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E
Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943
[TBL] [Abstract][Full Text] [Related]
28. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.
Lalande V; Truffot-Pernot C; Paccaly-Moulin A; Grosset J; Ji B
Antimicrob Agents Chemother; 1993 Mar; 37(3):407-13. PubMed ID: 8384811
[TBL] [Abstract][Full Text] [Related]
29. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
[TBL] [Abstract][Full Text] [Related]
30. [Status quo of pyrazinamide as an antituberculosis drug].
Kameda K
Kekkaku; 1995 Jul; 70(7):445-55. PubMed ID: 7564054
[TBL] [Abstract][Full Text] [Related]
31. Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs.
Liang Y; Wu X; Zhang J; Yang Y; Wang L; Bai X; Yu Q; Li N; Li Z
Scand J Immunol; 2011 Jul; 74(1):42-6. PubMed ID: 21352251
[TBL] [Abstract][Full Text] [Related]
32. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
Andries K; Verhasselt P; Guillemont J; Göhlmann HW; Neefs JM; Winkler H; Van Gestel J; Timmerman P; Zhu M; Lee E; Williams P; de Chaffoy D; Huitric E; Hoffner S; Cambau E; Truffot-Pernot C; Lounis N; Jarlier V
Science; 2005 Jan; 307(5707):223-7. PubMed ID: 15591164
[TBL] [Abstract][Full Text] [Related]
33. The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide.
Walubo A; Chan K; Woo J; Chan HS; Wong CL
Methods Find Exp Clin Pharmacol; 1991 Oct; 13(8):551-6. PubMed ID: 1956210
[TBL] [Abstract][Full Text] [Related]
34. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
[TBL] [Abstract][Full Text] [Related]
35. Treatment of extrapulmonary tuberculosis.
Dutt AK; Stead WW
Semin Respir Infect; 1989 Sep; 4(3):225-31. PubMed ID: 2688005
[TBL] [Abstract][Full Text] [Related]
36. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma.
Smith PJ; van Dyk J; Fredericks A
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S325-8; discussion S351-2. PubMed ID: 10593712
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.
Lenaerts AM; Chase SE; Cynamon MH
Antimicrob Agents Chemother; 2000 Nov; 44(11):3167-8. PubMed ID: 11036043
[TBL] [Abstract][Full Text] [Related]
38. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
[TBL] [Abstract][Full Text] [Related]
39. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
[TBL] [Abstract][Full Text] [Related]
40. Smear-negative pulmonary tuberculosis.
Dutt AK; Stead WW
Semin Respir Infect; 1994 Jun; 9(2):113-9. PubMed ID: 7973170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
